Jingrui Pharma develops small molecule antitumor drugs and degraders targeting difficult-to-treat cancer and autoimmune disease pathways, utilizing proprietary drug screening and optimization technologies. The company addresses the clinical need for effective therapies by accelerating the development of first-in-class treatments with a focus on differentiated drug candidates.
Funding
Funding not disclosed
Founders
Product
Problem
Many cancers and autoimmune diseases are difficult to treat due to complex biological pathways and a lack of effective drug targets. There is a clinical need for innovative therapies that can address these challenging targets and improve patient outcomes.
Solution
Jingrui Pharma is developing small molecule antitumor drugs and degraders that target previously undruggable cancer and autoimmune disease pathways. The company utilizes proprietary drug screening and optimization technologies to accelerate the development of first-in-class treatments. Jingrui Pharma focuses on creating differentiated drug candidates with the goal of providing innovative therapies for unmet clinical needs in China and globally.
Target Audience
The primary target audience includes patients suffering from cancers and autoimmune diseases, as well as healthcare providers seeking innovative treatment options for these conditions.
Features
- Focus on small molecule innovative drugs for difficult-to-drug targets.
- Development of targeted anti-tumor drugs and degraders.
- Proprietary drug screening and optimization technologies.
- Pipeline of first-in-class drug candidates.
- Focus on differentiated drug candidates.
- Development of innovative therapies for unmet clinical needs in oncology and autoimmune diseases.
- Development of technologies for new drug screening, optimization, and evaluation.